Organogenesis Holdings GAAP EPS of -$0.44 misses by $0.13, revenue of $37.2M misses by $6.1M

* Organogenesis Holdings press release [https://seekingalpha.com/pr/20506842-organogenesis-holdings-inc-reports-first-quarter-2026-financial-results] (ORGO [https://seekingalpha.com/symbol/ORGO]): Q1 GAAP EPS of -$0.44 misses by $0.13.
* Revenue of $37.2M (-57.1% Y/Y) misses by $6.1M.
* Net revenue from Advanced Wound Care products of $29.5 million, a decrease of 63% from the first quarter of 2025.
* Net revenue from Surgical & Sports Medicine products of $6.8 million, consistent with the first quarter of 2025.

*
For the year ending December 31, 2026, the Company now expects:

* Total net revenue between $270.0 million and $310.0 million vs $401.2M consensus, representing a decline in the range of 45% to 52%, as compared to total net revenue of $564.2 million for the year ended December 31, 2025.

* The 2026 total net revenue guidance range assumes a sequential improvement in revenue trends in the second quarter, however, at a more measured rate versus what the prior guidance assumed resulting in a first half revenue decline in the range of approximately 52% to 49% year over year. We continue to expect strong sequential revenue growth in the third and fourth quarters of 2026, however, the low-end of the guidance range now assumes a more prolonged recovery in market-related headwinds resulting in a second half revenue decline similar to the first half of 2026.

* Shares -8%.

MORE ON ORGANOGENESIS HOLDINGS

* Organogenesis: Clinical Win De-Risks 2026, Recovery In Sight [https://seekingalpha.com/article/4888977-organogenesis-clinical-win-de-risks-2026-recovery-in-sight]
* Organogenesis Facing Hard Times As It Adjusts To CMS Rule Changes [https://seekingalpha.com/article/4886651-organogenesis-facing-hard-times-as-it-adjusts-to-cms-rule-changes]
* Organogenesis Holdings Inc. (ORGO) Q4 2025 Earnings Call Transcript [https://seekingalpha.com/article/4876036-organogenesis-holdings-inc-orgo-q4-2025-earnings-call-transcript]
* Organogenesis Holdings Q1 2026 Earnings Preview [https://seekingalpha.com/news/4587439-organogenesis-holdings-q1-2026-earnings-preview]
* Organogenesis rises as PuraPlyAM succeeds in diabetic foot ulcers [https://seekingalpha.com/news/4572921-organogenesis-stock-up-puraplyam-succeeds]